FDA approved cabozantinib (CABOMETYX, Exelixis, Inc.)

On April 25, 2016, the U. S. Food and Drug Administration approved cabozantinib (CABOMETYX, Exelixis, Inc.) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.

http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm497483.htm

More News